Bet inhibitor - OmicsDI

Show results for

Unknown (711)
Genomics (616)
Transcriptomics (451)
Proteomics (33)
Other (17)
Clinical (3)
Metabolomics (3)
Methylation profiling (1)

Organisms

Homo sapiens (435)
Mus musculus (155)
Aerococcus urinae NBRC 15544 = CCUG 36881 (28)
Alteromonadales (28)
Bacteria (28)
Canis lupus familiaris (28)
Carya cathayensis (28)
Ectopseudomonas oleovorans CECT 5344 (28)
Ensifer adhaerens (28)
Enterococcus faecalis (28)
Saccharomyces cerevisiae (6)
Drosophila melanogaster (5)
Rattus norvegicus (4)
Caenorhabditis elegans (3)
Klebsiella pneumoniae subsp. pneumoniae MGH 78578 (2)
Papio hamadryas (2)
Schizosaccharomyces pombe (2)
Gadus morhua (2)
Plasmodium falciparum (2)
Influenza A virus (A/WSN/1933(H1N1)) (1)
Saccharomyces cerevisiae W303 (1)
Bacillus methanolicus (1)
Aspergillus nidulans (1)
Bacillus subtilis (1)
Hordeum vulgare (1)
Solanum lycopersicum (1)
Triticum aestivum (1)
Pseudomonas aeruginosa (1)
Gallus gallus (1)
synthetic construct (1)

Organisms

Homo sapiens (340)
Mus musculus (84)
Rattus norvegicus (4)
Drosophila melanogaster (2)

Repository

ENA (468)
geo (394)
biostudies-arrayexpress (220)
pride (28)
EGA (3)
MassIVE (3)
MetaboLights (3)
iProX (2)

Tissue

Cell culture (12)
Brain (4)
Blood (2)
Blood cell (1)
Epithelial cell (1)
Fibroblast (1)
Granulocyte (1)
Heart (1)
Hematopoietic progenitor cell antigen CD34 (human) (1)
Permanent cell line cell (1)
Spermatid (1)
Spleen (1)
T cell (1)
Testis (1)

Disease

Carcinoma (1)
Colorectal Neoplasms (1)
Neoplasms (1)
Acute leukemia (1)
Brain glioblastoma multiforme (1)
COVID-19 (1)
Essential thrombocythemia (1)
Human immunodeficiency virus infectious disease (1)
Melanoma (1)
Multiple myeloma (1)
Myelofibrosis (1)
Myeloproliferative neoplasm (1)
Pancreatic cancer (1)
Renal clear cell carcinoma (1)

Technology Type

Mass Spectrometry (28)
Shotgun proteomics (17)
Bottom-up proteomics (8)
SWATH MS (5)
NMR spectroscopy (1)
Mass spectrometry (1)
Mass spectrometry assay (1)
Data-dependent acquisition (1)

Instrument Platform

NextSeq 500 (13)
Illumina NovaSeq 6000 (9)
Illumina HiSeq 2500 (8)
NextSeq 550 (4)
TripleTOF 5600 (3)
MinION (2)
Illumina HiSeq 2000 (2)
BD Influx Cell Sorter (1)
I.DOT (Dispendix), C.WASH (CYTENA), Qubit Fluorometer (Thermo Fisher Scientific), Agilent TapeStation 4200 (1)
BD FACSDiscover S8 (1)
MoFlo XDP (Beckman Coulter) or a FACSAria II (Becton Dickinson) (1)
Fluidigm C1 autoprep system (1)
Gene Titan (1)
Illumina Genome Analyzer IIx (1)
Sony SH800S (1)
NextSeq 2000 (1)
DNBSEQ-G400 (1)
Illumina MiSeq (1)
Illumina HiSeq 4000 (1)
Nuclear Magnetic Resonance (NMR) - (1)
Liquid Chromatography MS - alternating - reverse-phase (1)
Liquid Chromatography MS - alternating - hilic (1)
Liquid Chromatography MS - negative - reverse phase (1)

Publication Date

2022 (56)
2016 (53)
2015 (51)
2020 (48)
2013 (47)
2026 (46)
2025 (44)
2024 (42)
2023 (37)
2018 (36)
2021 (35)
2017 (34)
2019 (29)
2014 (28)
2012 (21)
2010 (17)
2011 (11)
2009 (6)
2007 (4)
2008 (2)
2006 (1)

CHEBI ID

CHEBI:85363 (1)
CHEBI:89843 (1)
CHEBI:70959 (1)
CHEBI:48430 (1)
CHEBI:27856 (1)
CHEBI:30751 (1)
CHEBI:17790 (1)
CHEBI:15347 (1)
CHEBI:16236 (1)
CHEBI:17824 (1)
CHEBI:9349 (1)
CHEBI:7563 (1)
CHEBI:35932 (1)
CHEBI:422 (1)
CHEBI:16704 (1)
CHEBI:16857 (1)
CHEBI:15366 (1)
CHEBI:17750 (1)
CHEBI:36313 (1)
CHEBI:29864 (1)
CHEBI:18183 (1)
CHEBI:17634 (1)
CHEBI:15971 (1)
CHEBI:18050 (1)
CHEBI:16283 (1)
CHEBI:18295 (1)
CHEBI:15355 (1)
CHEBI:17568 (1)
CHEBI:15741 (1)
CHEBI:32816 (1)

Metabolite Name

Glycine (2)
Choline (2)
Creatinine (2)
Sodium 3-(trimethylsilyl)propionate (1)
Hexenoylcarnitine (Car(6:1)) (1)
4-(Dimethylamino)pyridine (1)
1-(1Z-Octadecenyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine (1)
N-Oleoyl-D-erythro-sphingosylphosphorylcholine (1)
Arsenobetaine (1)
L-Norvaline (1)
Oxotetradecadienoylcarnitine (Car(14:3-O)) (1)
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine (1)
Imiquimod (1)
[(Aminocarbonyl)(methyl)amino]acetic acid (1)
2-(2-Aminoethoxy)acetic acid (1)
Alpinetin (1)
2-Amino-3-methyl-imidazo[4,5-f]quinoline (IQ) (1)
1-Docosahexaenoyl-2-stearoyl-sn-glycero-3-phosphocholine (1)
Dihydrotachysterol (1)
Azeliragon (1)
Picoline (1)
Aminopicoline (1)
Tiglylcarnitine (Car(5:1)) (1)
Cysteine S-sulfate (1)
Fenobucarb (1)
Dibenzylamine (1)
Pyrimethanil (1)
N-Nitrosopyrrolidine (1)
Oxooctanoylcarnitine (Car(8:1-O)) (1)
.beta.-D-Glucopyranosiduronic acid, 4-(7-hydroxy-4-oxo-4H-1-benzopyran-3-yl)phenyl (1)

First Public Date

2024 (52)
2020 (50)
2022 (47)
2019 (45)
2025 (42)
2023 (40)
2021 (38)
2026 (34)
2017 (32)
2018 (26)
2014 (25)
2016 (16)
2015 (15)
2013 (6)

Modification

Not available (1)

Study status

Terminated (1)
Recruiting (1)
Not yet recruiting (1)

Study type

Transcription profiling by array (88)
RNA-seq of coding RNA (40)
ChIP-seq (36)
ChIP-chip by tiling array (18)
RNA-seq of coding RNA from single cells (11)
Transcription profiling by tiling array (5)
Comparative genomic hybridization by array (3)
Other (3)
DNA-seq (3)
Interventional (3)
Unknown experiment type (2)
Animal - High-throughput sequencing (2)
Methylation profiling by high throughput sequencing (2)
Animal - Single-cell sequencing (1)
Translation profiling (1)
Cell line - High-throughput sequencing (1)
Capture-C (1)
Single nucleus RNA sequencing (1)
RNA-seq of total RNA (1)
RNA-seq of non coding RNA (1)

Release Date

2022 (95)
2015 (79)
2021 (77)
2016 (74)
2020 (67)
2018 (67)
2023 (64)
2019 (62)
2013 (61)
2017 (52)
2024 (51)
2025 (48)
2014 (41)
2012 (27)
2026 (16)
2010 (16)
2011 (13)
2009 (7)
2007 (5)
2008 (3)
2006 (2)
2005 (1)
2000 (1)

Lab affiliation

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA (3)
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (3)
The Drug Discovery Lab, Mary S. Easton Center for Alzheimer’s Disease Research, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA (2)
- Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil (1)
1 Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, PR China 2 Department of Microbiology and Immunology, Tongji University School of Medicine, Shanghai 200049, PR China 3 Clinical Translation Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China. (1)
Core Unit Proteomics, Berlin Institute of Health at Charite - Universitaetsmedizin Berlin and Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany (1)
Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany (1)
Director, Proteomics and Metabolomics Facility, Center for Open Research Resources and Equipment, University of Connecticut, Storrs, CT, USA (1)
EDyP (1)
Facutly of Science, University of Geneva (1)
Georgetown University, USA (1)
IRIC-Université de Montréal (1)
Institute for Biological Resources and Marine Biotechnologies (CNR), Italian National Research Council, Messina, Italy (1)
Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland (1)
Leukemia Department, MD Anderson Cancer Center, Houston, TX 77030 (1)
Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Pharmacology, Laboratory of Pharmacology and Brain Biostructure, Smetna Str. 12, 31-343 Krakow, Poland (1)
New York University (1)
School of Life and Environmental Sciences, Charles Perkins Centre, University of Sydney, Australia (1)
Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Germany (1)
Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research and Jewish General Hospital, and McGill University, Montréal, Québec, Canada Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada (1)
The Institute of Cancer research (1)
University Medical Center, Department of Clinical Chemistry, Core Facility Proteomics (1)
University of Geneva, Switzerland (1)

Location

United States (2)
United Kingdom (1)
Spain (1)

Keyword

INCB057643 (1)
Azacitidine (1)
Pembrolizumab (1)
Antineoplastic Agents, Immunological (1)
Antibodies (1)
Immunoglobulins (1)
Antibodies, Monoclonal (1)
CRC (1)
Capecitabine (1)
Cetuximab (1)

Previous page
1 / 184
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 184
Next page

Sort by:

Relevance

Page size

Streptococcus anginosus promotes hepatocellular carcinoma progression and BET inhibitor resistance by inducing BRD4 lactylation

Hepatocellular carcinoma (HCC) is a highly aggressive form of carcinoma with a poor prognosis. Diagnostic markers and potential therapeutic targets for HCC are urgently needed. Here, we demonstrate that fecal microbiota transplantation (FMT) using stool samples from HCC patients significantly pro...

2025-12-05 | MTBLS12398 | MetaboLights

Genome wide expression analysis of BET inhibitor resistance

Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluation ...

ORGANISM(S): Mus musculus

2015-09-15 | E-GEOD-63575 | biostudies-arrayexpress

Genome wide expression analysis of BET inhibitor resistance [RNA-seq]

Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers1,2. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluati...

ORGANISM(S): Mus musculus

2015-09-15 | E-GEOD-63681 | biostudies-arrayexpress

ChIP of BET proteins in iBET resistance [ChIP-seq]

Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers1,2. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluati...

ORGANISM(S): Mus musculus

2015-09-15 | E-GEOD-63682 | biostudies-arrayexpress

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

We analyzed transcriptional changes in 4 prostate cancer cell lines following treatment with the BET inhibitor I-BET762 using Affymetrix Human Genome U133 Plus 2.0 Arrays. Four prostate cancer cell lines (NCI-H660, VCaP, LNCaP, PC-3) were treated with DMSO (control) or I-BET762 at 0.5uM or 10uM con...

ORGANISM(S): Homo sapiens

2014-03-31 | E-GEOD-56352 | biostudies-arrayexpress

Functions of BET proteins in GATA1-mediated transcription [expression array]

Role of bromodomain and extra-terminal motif (BET) proteins in GATA1-null erythrolbasts (G1E) and in differentiation induced by activation of conditional GATA1 tested by addition of BET inhibitor JQ1 (250nM) Array protocols were conducted as described in the Ambion WT Expression Manual and the Affym...

ORGANISM(S): Mus musculus

2015-02-23 | E-GEOD-62709 | biostudies-arrayexpress

Functions of BET proteins in GATA1-mediated transcription [ChIP-seq]

Transcription factor GATA1 binding in erythroblasts in the presence and absence of BET inhibitor JQ1, and BET protein BRD3 and BRD4 binding in erythroblasts in the presence and absence of GATA1. Inhibitors of Bromodomain and Extra-Terminal motif proteins (BETs) are being evaluated for the treatment...

ORGANISM(S): Mus musculus

2015-02-23 | E-GEOD-62736 | biostudies-arrayexpress

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer (ChIP-Seq)

Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. The development and progression to CRPC following androgen ablation therapy is predominantly driven by unregulated androgen receptor (AR) signaling1-3. Despite the success of recently approved...

ORGANISM(S): Homo sapiens

2014-04-25 | E-GEOD-55062 | biostudies-arrayexpress

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [ChIP-Seq]

Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. Here we report the preferential and high sensitivity of TNBCs to BET bromodomain inhibitors such as JQ1 manifested by cell cycle arrest in early G1, apoptosis, and induct...

ORGANISM(S): Homo sapiens

2016-01-07 | E-GEOD-63581 | biostudies-arrayexpress

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer [Chem-Seq]

ORGANISM(S): Homo sapiens

2016-01-07 | E-GEOD-63284 | biostudies-arrayexpress

Previous page
1 / 184
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 184
Next page

Sort by:

Relevance

Page size

1835 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Modification

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets